首页 | 官方网站   微博 | 高级检索  
     

红金消结胶囊联合醋酸亮丙瑞林治疗子宫内膜异位症临床研究
引用本文:余晓玲,徐经安,陈荣荣. 红金消结胶囊联合醋酸亮丙瑞林治疗子宫内膜异位症临床研究[J]. 新中医, 2024, 56(2): 100-104
作者姓名:余晓玲  徐经安  陈荣荣
作者单位:安阳市妇幼保健院妇科,河南安阳455000
摘    要:目的:观察红金消结胶囊联合醋酸亮丙瑞林治疗子宫内膜异位症的临床疗效。方法:选取82例子宫内膜异位症患者,按随机数字表法分为对照组与治疗组各41例。对照组给予注射用醋酸亮丙瑞林缓释微球治疗,治疗组在对照组基础上联合红金消结胶囊联合治疗。比较2组临床疗效与不良反应发生率,以及2组治疗前后中医证候评分、血清糖类抗原125 (CA125)、抗子宫内膜抗体(EMAb)、脂联素(APN)、肝细胞生长因子(HGF)水平、子宫体积、子宫内膜厚度、包块直径。结果:治疗组总有效率为95.12%,对照组为78.05%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组中医证候评分均较治疗前降低(P<0.05),且治疗组中医证候评分低于对照组(P<0.05)。治疗后,2组子宫内膜厚度、子宫体积、包块直径均较治疗前缩小(P<0.05),且治疗组上述3项指标均小于对照组(P<0.05)。治疗后,2组血清CA125、EMAb、HGF水平均较治疗前降低(P<0.05),APN水平较治疗前升高(P<0.05);且治疗组CA125、EMAb、HGF水平低于对照组(P<...

关 键 词:子宫内膜异位症  红金消结胶囊  注射用醋酸亮丙瑞林缓释微球  中医证候评分  糖类抗原125  抗子宫内膜抗体

Clinical Study on Hongjin Xiaojie Capsules Combined with Leuprorelin Acetate forEndometriosis
YU Xiaoling,XU Jing''an,CHEN Rongrong. Clinical Study on Hongjin Xiaojie Capsules Combined with Leuprorelin Acetate forEndometriosis[J]. JOURNAL OF NEW CHINESE MEDICINE, 2024, 56(2): 100-104
Authors:YU Xiaoling  XU Jing''an  CHEN Rongrong
Affiliation:Department of Gynecology,Anyang Maternal and Child Health Hospital,Anyang Henan 455000,China
Abstract:Abstract: Objective: To observe the clinical effect of Hongjin Xiaojie Capsules combined withLeuprorelin Acetate for endometriosis. Methods:A total of 82 patients with endometriosis were randomlydivided into the control group and the treatment group,with 41 cases in each group. The control group wastreated with Leuprorelin Acetate Microspheres Sustained Release for Injection, and the treatment groupwas supplemented with Hongjin Xiaojie Capsules based on the treatment of the control group. The clinicaleffects and adverse reaction rates were compared between the two groups. The changes in traditionalChinese medicine (TCM) syndrome scores,levels of carbohydrate antigen 125 (CA125),anti endometrialantibody (EMAb), adiponectin (APN) and hepatocyte growth factor (HGF) in serum, the uterine volume,endometrial thickness and mass diameter were compared before and after treatment. Results: The total effective rate was 95.12% in the treatment group,and 78.05% in the control group,the difference beingsignificant (P<0.05). After treatment,the TCM syndrome scores in the two groups were decreased whencompared with those before treatment (P<0.05), and the TCM syndrome score in the treatment groupwere lower than those in the control group (P<0.05). After treatment,the endometrial thickness,uterinevolume and mass diameter in the two groups were decreased when compared with those before treatment(P<0.05),and the above three indexes in the treatment group were smaller than that in the control group(P<0.05). After treatment, the levels of CA125, EMAb, and HGF in serum in the two groups weredecreased when compared with those before treatment (P<0.05),and the levels of APN were increasedwhen compared with those before treatment (P<0.05);the levels of CA125,EMAb and HGF in serum inthe treatment group were lower than those in the control group (P<0.05),and the level of APN was higherthan that in the control group (P<0.05). The incidence of adverse reactions was 9.76% in the control group,and 4.88% in the treatment group,there being no significant difference between the two groups (P>0.05).Conclusion:Hongjin Xiaojie Capsules combined with Leuprorelin Acetate Microspheres Sustained Releasefor Injection has a significant curative effect in treating endometriosis, which can improve the clinicalsymptoms and signs, regulate the levels of related serum cytokines in serum, and has no adversereactions of the treatment.
Keywords:Keywords: Endometriosis; Hongjin Xiaojie Capsules; Leuprorelin Acetate Microspheres SustainedRelease for Injection; Traditional Chinese medicine syndrome scores; Carbohydrate antigen 125;Endometrial antibody
点击此处可从《新中医》浏览原始摘要信息
点击此处可从《新中医》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号